US Stock MarketDetailed Quotes
MYNZ Mainz Biomed
- 4.600
- +0.060+1.32%
Close Dec 27 16:00 ET
- 4.641
- +0.041+0.89%
Post 20:01 ET
10.22MMarket Cap-0.10P/E (TTM)
4.699High4.300Low65.58KVolume4.550Open4.540Pre Close298.73KTurnover3.07%Turnover RatioLossP/E (Static)2.22MShares48.80052wk High-2.47P/B9.82MFloat Cap3.65052wk Low--Dividend TTM2.13MShs Float1200.000Historical High--Div YieldTTM8.79%Amplitude3.650Historical Low4.554Avg Price1Lot Size
Mainz Biomed Stock Forum
Sign in to post a comment
1
$Evoke Pharma (EVOK.US)$ $Mainz Biomed (MYNZ.US)$ $Allarity Therapeutics (ALLR.US)$ $NLS Pharmaceutics (NLSP.US)$ $Gelteq (GELS.US)$ $Real Messenger (RMSG.US)$ $PMGC Holdings (ELAB.US)$ $DallasNews (DALN.US)$ $Avalon GloboCare (ALBT.US)$ $Psyence Biomedical (PBM.US)$ $XChange TEC (XHG.US)$ $Trio Petroleum (TPET.US)$ $PainReform (PRFX.US)$
📊⚡️📊
📊⚡️📊
1
$Mainz Biomed (MYNZ.US)$
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Thursday, 19th December at 8:01 am
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE: DGX), a leading ...
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Thursday, 19th December at 8:01 am
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE: DGX), a leading ...
1
$Mainz Biomed (MYNZ.US)$ Reuters· just
Mainz Biomed Forms Agreement With Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed Forms Agreement With Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
The stock market has shown promising signs of growth, driven by strong earnings reports and positive economic indicators. Companies like Nvidia have continued to impress with their AI innovations, leading analysts to maintain a bullish outlook despite recent market fluctuations. $NVIDIA (NVDA.US)$ ’s recent earnings report was described as “flawless,” and the company’s Blackwell AI chip is expected to boost its growth prospects further.
Apple’s stoc...
Apple’s stoc...
8
2
$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
30
31
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Mainz Biomed (MYNZ.US)$ Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
13 MINUTES AGO, 8:00 PM EST
VIA GLOBENEWSWIRE
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the ...
13 MINUTES AGO, 8:00 PM EST
VIA GLOBENEWSWIRE
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the ...
$Mainz Biomed (MYNZ.US)$
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
1 minute ago, 5:00 PM PST
Via GlobeNewswire
MYNZ
Share
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 1,367,521 units, with each unit...
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
1 minute ago, 5:00 PM PST
Via GlobeNewswire
MYNZ
Share
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 1,367,521 units, with each unit...
1
Please take note of the following acronyms
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
114
38
6
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
105029491 : What kind of picture is this?